Table 4 Summary of treatment-emergent adverse events (regardless of causality) in either dosing subgroup
Angiotensin II > 5 ng kg−1 min−1 (n = 84) | Angiotensin II ≤ 5 ng kg−1 min−1 (n = 79) | |
|---|---|---|
Any grade, n (%) | 76 (90.5) | 66 (83.5) |
Grade 3/4, n (%) | 64 (76.2) | 43 (54.4) |
Serious adverse events, n (%) | 64 (76.2) | 35 (44.3) |
Adverse events resulting in discontinuation, n (%) | 19 (22.6) | 4 (5.1) |
Fatal adverse events, n (%) | 0 | 1 (1.3) |